Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EPS (Weighted Average and Diluted) (2020 - 2025)

Burning Rock Biotech has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.9 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 80.81% year-over-year to -$0.9; the TTM value through Dec 2025 reached -$0.9, up 80.81%, while the annual FY2025 figure was -$0.07, 84.78% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.9 at Burning Rock Biotech, up from -$4.69 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.9 in Q4 2025 and troughed at -$12.87 in Q4 2022.
  • A 5-year average of -$4.66 and a median of -$2.9 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 343.79% in 2022 and later surged 84.97% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$2.9 in 2021, then crashed by 343.79% to -$12.87 in 2022, then surged by 84.97% to -$1.93 in 2023, then tumbled by 142.65% to -$4.69 in 2024, then soared by 80.81% to -$0.9 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BNR at -$0.9 in Q4 2025, -$4.69 in Q4 2024, and -$1.93 in Q4 2023.